-+ 0.00%
-+ 0.00%
-+ 0.00%

Compass Therapeutics to report COMPANION-002 secondary endpoints for tovecimig in biliary cancer

PUBT·04/24/2026 20:02:06
Listen to the news
Compass Therapeutics to report COMPANION-002 secondary endpoints for tovecimig in biliary cancer
  • Compass Therapeutics scheduled webcast for April 27, 2026 to present topline secondary endpoint results from Phase 2/3 COMPANION-002 study in advanced biliary tract cancer.
  • Readout will cover how tovecimig, a DLL4 x VEGF-A bispecific antibody, performed in combination with paclitaxel.
  • Event positions Compass to update investors on clinical progress for lead oncology program in biliary tract cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.